Monday 16 March | |
Ceres Power | Half Year Results |
Old Mutual | Full Year Results |
Dialight | Full Year Results |
SThree | Trading Statement |
Volution Group | Half Year Results |
Telit Communications | Full Year Results |
Tuesday 17 March | |
Litigation Capital | Half Year Results |
Gamma Communcations | Full Year Results |
ContourGlobal | Full Year Results |
Smart Metering Systems | Full Year Results |
Harworth Group | Full Year Results |
Tritax Big Box | Full Year Results |
Good Energy | Full Year Results |
Gamesys | Full Year Results |
Baillie Gifford Shin Nippon | Full Year Results |
ScS Group | Half Year Results |
Polypipe | Full Year Results |
Antofagasta | Full Year Results |
Softcat | Half Year Results |
e-therapeutics | Full Year Results |
TI Fluid Systems | Full Year Results |
Vectura | Full Year Results |
Ferguson | Half Year Results |
Wednesday 18 March | |
WM Morrison Supermarkets | Full Year Results |
MJ Hudson | Half Year Results |
Judges Scientific | Full Year Results |
Centaur Media | Full Year Results |
Pendragon | Full Year Results |
Empiric Student Property | Full Year Results |
Strix Group | Full Year Results |
Empresaria | Full Year Results |
Cello Health | Full Year Results |
Accesso Technolgy | Full Year Results |
Ferrexpo | Full Year Results |
EMIS Group | Full Year Results |
Tribal Group | Full Year Results |
S4 Capital | Full Year Results |
Restore | Full Year Results |
Thursday 19 March | |
Next | Full Year Results |
Ocado Group | Q1 Results |
Halma | trading Statement |
Sanne Group | Full Year Results |
SafestyleUK | Full Year Results |
Portmeirion Group | Full Year Results |
Capital Drilling | Full Year Results |
Everyman Media Group | Full Year Results |
LoopUp | Full Year Results |
Genel Energy | Full Year Results |
Tclarke | Full Year Results |
Hurricane Energy | Full Year Results |
IG Group | Q3 Results |
FW Thorpe | Full Year Results |
Sportech | Full Year Results |
Energean Oil & Gas | Full Year Results |
Gym Group | Full Year Results |
Onesavings Bank | Full Year Results |
Friday 20 March | |
Caledonia | Full Year Results |
Investec | Trading Statement |
Faron Pharmaceuticals | Full Year Results |
Manchester & London Investment Trust | Half Year Results |
JD Wetherspoon | Half Year Results |
Copyright 2020 Alliance News Limited. All Rights Reserved. |
IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.
Read more